05:26:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-09-19 Kvartalsrapport 2024-Q2
2024-06-07 Årsstämma 2024
2024-04-18 Bokslutskommuniké 2023
2023-09-28 Kvartalsrapport 2023-Q2
2023-06-12 Ordinarie utdelning EXTX 0.00 NOK
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaEuronext Growth Oslo
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2022-11-22 09:00:00
OSLO/PHOENIX, Arizona, USA, 22 Nov, 2022: 
EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a Norwegian clinical
stage precision health company utilising Acoustic Cluster Therapy (ACT®) across
multiple therapeutic areas, and the Phoenix-based Translational Genomics
Research Institute (TGen), part of City of Hope, today announce the publication
of a paper in the peer-reviewed Journal of Controlled Release titled "Effect of
Acoustic Cluster Therapy combined with chemotherapy in a mouse model of
pancreatic cancer". This study was partly funded by a grant from Innovation

The ACT® technology is based on microclusters of microbubble-microdroplets and
when sonicated, vaporisation of the microdroplets lead to the formation of
larger ACT® bubbles. The formation and subsequent oscillation of the ACT®
bubbles in the microvasculature produces mechanical bio-effects that enhance
drug delivery and efficacy. TGen have evaluated the effectiveness of the
technology in a preclinical pancreatic cancer model, and the results
demonstrated that ACT® significantly improved the therapeutic efficacy of two
cornerstone treatment regimens in the management of pancreatic cancer. The best
effect was seen when drug administration preceded the ACT® treatment, but
interestingly the anti-tumour effect was almost maintained when the drugs were
administered after ACT®-treatment was finalized. Similar observations have been
made in previous work with ACT® combined with chemotherapy. This suggests that
the main effect of ACT® is not on the drug itself, but rather affects the
vasculature and tumour microenvironment to facilitate drug delivery and
therapeutic response.

For the full article, please follow:

"Our study demonstrates that ACT can significantly improve the effect of two
standard of care chemotherapeutic regimens in a patient-derived pancreatic
cancer model in mice. The ACT treatment resulted in a significant increase in
tumour growth inhibition and a 7.2 times higher probability of having a complete
remission of the tumour compared to the chemotherapeutics alone." said Dr.
Haiyong Han, a Professor in TGen's Molecular Medicine Division and the study's
senior author.

"Pancreatic cancer is known to be notoriously resistant to treatment, in part
because of poor drug delivery." said Dr. Daniel Von Hoff, TGen's Distinguished
Professor and one of the national's lead experts in pancreatic cancer. "The
results from the study are some of the most encouraging ones we have seen in
preclinical models for pancreatic cancer, and we look forward to being involved
in the further development of this promising technology."

Dr Per Walday, CEO of EXACT-Tx, commented: "We are very pleased to announce the
publication of these encouraging results from our collaboration with the
prestigious Translational Genomics Research Institute in Phoenix, Arizona. These
data are produced in a model with patient-derived material, which more closely
resembles the tumour tissue characteristics of pancreatic cancer in man compared
to cell-line based models. The results further underpin the established
potential of ACT to enhance standard of care treatments for difficult to treat
cancers and we look forward to progressing our clinical development program in
this area."

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases.

About TGen, part of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based
non-profit organization dedicated to conducting groundbreaking research with
life-changing results. TGen is part of City of Hope, a world-renowned
independent research and treatment center for cancer, diabetes, and other
life-threatening diseases. This precision medicine affiliation enables both
institutes to complement each other in research and patient care, with City of
Hope providing a significant clinical setting to advance scientific discoveries
made by TGen. TGen is focused on helping patients with neurological disorders,
cancer, diabetes, and infectious diseases through cutting-edge translational
research (the process of rapidly moving research toward patient benefit). TGen
physicians and scientists work to unravel the genetic components of both common
and complex rare diseases in adults and children. Working with collaborators in
the scientific and medical communities worldwide, TGen makes a substantial
contribution to help patients through efficiency and effectiveness of the
translational process. Follow TGen on Facebook, LinkedIn and Twitter @TGen.

Media Contact
Galen P. Perry, Sr. Vice President, Marketing & Communications
Phone: +1 602.343.8423
Email: gperry@tgen.org

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.
For further information on ACT®, please visit www.exact-tx.com

Media Contact
Per Walday, CEO
Phone: +47 91793429
Email: per.walday@exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause Actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.